We should look at these challenges holistically and think about better fiscal/social engineering of our marketplaces. Alvin Roth's book, "Who Gets What and Why", is a good introduction to identifying market failures and thinking about how to address them.
The whole point is that, past a certain point, it really isn't.
It can actually be harder to get access to new therapies in countries with universal healthcare because they’re more uniform and strict in what they allow.
For a relatable example: The UK just raised the age of eligibility for COVID vaccines all the way up to 75 years old: https://www.mirror.co.uk/news/health/covid-russian-roulette-... Contrast this with the US where COVID vaccine coverage is a basic expectation of health insurance for all ages. And that’s for a simple, cheap medicine without step therapy! It doesn’t matter if your doctor thinks you need it, the rules are set from the top.
This is something Americans with strong opinions about healthcare but little time spent researching it never seem to know.
There are other things to complain about of course, but the rules for what's covered ate generally logical. Non-covered medication is affordable to, which helps.
https://www.boots.com/online/pharmacy-services/covid-19-vacc...
THe most appropriate treatment is required, not "step therapy". For antibiotics this makes sense, as last mile, powerful antibiotics need to be used sparingly.
The same with cancer, it'll be treated according to the requirements of the cancer, with guidance from nice about the most effective therapy.
Is it perfect? no.
Does it lead to mistakes? yes.
It is better than american style insurance denying care based entirely on price? 100%
That wasn't a sure thing this past year and there's always a risk it won't be next year. (https://www.pbs.org/newshour/health/fact-checking-rfk-jr-s-c...)
This is especially true of patent medicines, where it's government enforced artificial scarcity.